Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Gene expression profile alone is inadequate in predicting complete response in multiple myeloma.

Amin SB, Yip WK, Minvielle S, Broyl A, Li Y, Hanlon B, Swanson D, Shah PK, Moreau P, van der Holt B, van Duin M, Magrangeas F, Pieter Sonneveld P, Anderson KC, Li C, Avet-Loiseau H, Munshi NC.

Leukemia. 2014 Nov;28(11):2229-34. doi: 10.1038/leu.2014.140. Epub 2014 Apr 15.

2.

Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous transplantation.

Terragna C, Renzulli M, Remondini D, Tagliafico E, Di Raimondo F, Patriarca F, Martinelli G, Roncaglia E, Masini L, Tosi P, Zamagni E, Tacchetti P, Ledda A, Brioli A, Angelucci E, Testoni N, Marzocchi G, Galieni P, Gozzetti A, Martello M, Dico F, Mancuso K, Cavo M.

Ann Hematol. 2013 Sep;92(9):1271-80. doi: 10.1007/s00277-013-1757-6. Epub 2013 May 10.

PMID:
23660628
3.

The molecular characterization and clinical management of multiple myeloma in the post-genome era.

Zhou Y, Barlogie B, Shaughnessy JD Jr.

Leukemia. 2009 Nov;23(11):1941-56. doi: 10.1038/leu.2009.160. Epub 2009 Aug 6. Review.

4.

A novel measure of chromosome instability can account for prognostic difference in multiple myeloma.

Chung TH, Mulligan G, Fonseca R, Chng WJ.

PLoS One. 2013 Jun 20;8(6):e66361. doi: 10.1371/journal.pone.0066361. Print 2013.

5.

Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.

Kim JS, Kim K, Cheong JW, Min YH, Suh C, Kim H, Jo DY, Ryoo HM, Yoon SS, Lee JH; Korean Multiple Myeloma Working Party.

Biol Blood Marrow Transplant. 2009 Apr;15(4):463-70. doi: 10.1016/j.bbmt.2008.12.512.

6.

Gene expression profiling in multiple myeloma--reporting of entities, risk, and targets in clinical routine.

Meissner T, Seckinger A, Rème T, Hielscher T, Möhler T, Neben K, Goldschmidt H, Klein B, Hose D.

Clin Cancer Res. 2011 Dec 1;17(23):7240-7. doi: 10.1158/1078-0432.CCR-11-1628. Epub 2011 Oct 10.

7.

Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics.

Shaughnessy JD Jr, Haessler J, van Rhee F, Anaissie E, Pineda-Roman M, Cottler-Fox M, Hollmig K, Zangari M, Mohiuddin A, Alsayed Y, Grazziutti M, Epstein J, Crowley J, Barlogie B.

Br J Haematol. 2007 Jun;137(6):530-6. Epub 2007 May 9.

PMID:
17489983
8.

Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma.

Sarasquete ME, Martínez-López J, Chillón MC, Alcoceba M, Corchete LA, Paiva B, Puig N, Sebastián E, Jiménez C, Mateos MV, Oriol A, Rosiñol L, Palomera L, Teruel AI, González Y, Lahuerta JJ, Bladé J, Gutiérrez NC, Fernández-Redondo E, González M, San Miguel JF, García-Sanz R.

Br J Haematol. 2013 Oct;163(2):223-34. doi: 10.1111/bjh.12519. Epub 2013 Aug 16.

PMID:
23952215
9.

Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.

Pineda-Roman M, Zangari M, Haessler J, Anaissie E, Tricot G, van Rhee F, Crowley J, Shaughnessy JD Jr, Barlogie B.

Br J Haematol. 2008 Mar;140(6):625-34. doi: 10.1111/j.1365-2141.2007.06921.x.

10.

Tumor cell gene expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in multiple myeloma.

Burington B, Barlogie B, Zhan F, Crowley J, Shaughnessy JD Jr.

Clin Cancer Res. 2008 Aug 1;14(15):4821-9. doi: 10.1158/1078-0432.CCR-07-4568.

11.

Feature selection and classification of MAQC-II breast cancer and multiple myeloma microarray gene expression data.

Liu Q, Sung AH, Chen Z, Liu J, Huang X, Deng Y.

PLoS One. 2009 Dec 11;4(12):e8250. doi: 10.1371/journal.pone.0008250.

12.

[Genetic tools for risk-stratification in multiple myeloma].

Braggio E, Albarracín Garramuño F.

Medicina (B Aires). 2013;73(4):369-75. Spanish.

13.

Advances in biology and therapy of multiple myeloma.

Barillé-Nion S, Barlogie B, Bataille R, Bergsagel PL, Epstein J, Fenton RG, Jacobson J, Kuehl WM, Shaughnessy J, Tricot G.

Hematology Am Soc Hematol Educ Program. 2003:248-78. Review.

PMID:
14633785
14.

The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma.

Johnson SK, Heuck CJ, Albino AP, Qu P, Zhang Q, Barlogie B, Shaughnessy JD Jr.

Int J Hematol. 2011 Oct;94(4):321-33. doi: 10.1007/s12185-011-0948-y. Epub 2011 Oct 15. Review.

15.

Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.

Harousseau JL, Attal M, Leleu X, Troncy J, Pegourie B, Stoppa AM, Hulin C, Benboubker L, Fuzibet JG, Renaud M, Moreau P, Avet-Loiseau H.

Haematologica. 2006 Nov;91(11):1498-505. Epub 2006 Oct 17.

16.

[Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].

Huang B, Li J, Liu J, Gu J, Zheng D, Xu D, Zou W, Wang H.

Zhonghua Nei Ke Za Zhi. 2014 Nov;53(11):865-72. Chinese.

PMID:
25586356
17.

Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.

Nair B, van Rhee F, Shaughnessy JD Jr, Anaissie E, Szymonifka J, Hoering A, Alsayed Y, Waheed S, Crowley J, Barlogie B.

Blood. 2010 May 27;115(21):4168-73. doi: 10.1182/blood-2009-11-255620. Epub 2010 Feb 2.

18.

Gene expression risk signatures maintain prognostic power in multiple myeloma despite microarray probe set translation.

Hermansen NE, Borup R, Andersen MK, Vangsted AJ, Clausen NT, Kristensen DL, Nielsen FC, Gimsing P.

Int J Lab Hematol. 2016 Jun;38(3):298-307. doi: 10.1111/ijlh.12486. Epub 2016 Mar 29.

PMID:
27027250
19.

Low-risk identification in multiple myeloma using a new 14-gene model.

Chen T, Berno T, Zangari M.

Eur J Haematol. 2012 Jul;89(1):28-36. doi: 10.1111/j.1600-0609.2012.01792.x.

PMID:
22620863
20.
Items per page

Supplemental Content

Write to the Help Desk